At the news
? NEUTRALIMPACT 6/10 8-K filed Jul 20, 2026 at 17:26 ET
Personalis (PSNL) entered into a definitive merger agreement with Tempus AI (TEM) on July 20, 2026. PSNL shareholders will receive Tempus Class A common stock based on a variable exchange ratio (floor of 0.3356 if TEM ≤ $48.42, otherwise $16.25 / TEM VWAP), with Tempus having the option to pay cash for up to 50% of shares at $16.25 per share. The deal, structured as a tax-free reorganization, requires PSNL stockholder approval, HSR clearance, and other customary conditions, with a termination fee of ~$76.8 million each way. Merck, holding ~13% of PSNL, has agreed to vote in favor via a voting agreement.
- Merger consideration: Tempus Class A common stock with exchange ratio = 0.3356 if TEM ≤ $48.42, else $16.25 / TEM VWAP; Tempus may elect cash for up to 50% of shares at $16.25/share
- Merck Sharp & Dohme LLC, holding ~13% of PSNL, entered into a voting agreement to support the deal
- Termination fee of approximately $76.8 million payable by either party under specified circumstances
- Conditions include PSNL stockholder approval, HSR waiting period expiration, effectiveness of Form S-4, and tax opinion
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access